Ravasio, R., R. Viti, and A. S. Roscini. “Cost Per Responder for Vedolizumab and Ustekinumab in Crohn’s Disease Patients After Failure of TNF-α Inhibitors in Italy”. AboutOpen, vol. 10, no. 1, Jan. 2023, pp. 13-21, doi:10.33393/ao.2023.2515.